Nuclear FAH Enzyme Linked to Breast Cancer Treatment Resistance
Researchers identified a protein that may hinder hormone-receptor-positive breast cancer therapy effectiveness.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Do you feel new cancer research findings significantly improve how you view future treatment options?
Scientists have discovered that the enzyme nuclear fumarylacetoacetate hydrolase (FAH) promotes resistance to standard CDK4/6 inhibitor treatments in HR-positive breast cancer. This biomarker could help identify patients who may need alternative therapeutic approaches.
Why it matters
Identifying this resistance mechanism offers a potential path to improve outcomes for patients whose tumors do not respond to existing standard therapies. This finding helps clarify why roughly one-fifth of HR-positive breast cancer cases currently fail to respond to treatment from the start.
A study published in Science Advances analyzed patient-derived organoids and tumor samples to confirm that nuclear FAH translocation occurs during CDK4/6 inhibition. The researchers established that FAH interacts with CDK9 to drive tumor survival, though clinical confirmation is pending.
The players
Beth Israel Deaconess Medical Center
A teaching hospital and research institution where the study team conducted the investigation.
Boston Children's Hospital
A pediatric academic medical center that hosted the study's co-senior author.
The details
Normally found in the cytoplasm, FAH translocates to the cell nucleus when the body is under the stress of CDK4/6 inhibition. Once in the nucleus, it binds with CDK9 to activate specific target genes that allow the cancer cells to bypass treatment effects. Disabling this interaction between FAH and CDK9 in laboratory models was shown to restore sensitivity to the standard inhibitor therapy.
Timeline
October 7, 2026: Research findings were published in Science Advances.
Health Landscape
This research advances our understanding of metabolic drivers in cancer beyond the established genomic profiles found in The Cancer Genome Atlas. It aligns with ongoing efforts to move toward precision oncology by predicting therapy response before treatment begins.
Patients with HR-positive breast cancer should discuss current clinical trial landscape or testing options with their oncology team. While this study is an important laboratory finding, it does not currently change standard treatment protocols for individuals already undergoing therapy.
The takeaway
Understanding how tumor cells develop treatment resistance is the first step toward creating more personalized cancer therapies. If you are currently in treatment for breast cancer, consult your physician about whether your specific diagnostic profile has been evaluated for resistance indicators.
Further reading
For more information on the latest research and standard treatment approaches, visit our Cancer section.
Source note: This article includes information reported by Inside Precision Medicine.
Live Poll
Do you feel new cancer research findings significantly improve how you view future treatment options?
